1.
Bioorg Med Chem Lett
; 11(14): 1911-4, 2001 Jul 23.
Article
in English
| MEDLINE
| ID: mdl-11459659
ABSTRACT
This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.
Subject(s)
Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacology , ErbB Receptors/antagonists & inhibitors , Quinazolines/pharmacology , Administration, Oral , Carcinoma, Squamous Cell/metabolism , Gefitinib , Humans , KB Cells/cytology , Quinazolines/chemical synthesis , Sensitivity and Specificity , Tumor Cells, Cultured/cytology , Tumor Cells, Cultured/metabolism
2.
N Z Med J
; 98(776): 252, 1985 Apr 10.
Article
in English
| MEDLINE
| ID: mdl-3857506